| Test Name |
ABL Kinase Mutation Analysis |
| Also Known As |
Gleevec Resistance |
| Panel? |
No |
| Related Tests |
5179-7; 5265-4; 5268-8; |
| Clinical Utility and/or Limitations |
Imatinib mesylate (Gleevec®) binds to the ABL kinase locus and functions as a competitive inhibitor of the ATP-binding site of BCR/ABL, thereby preventing tyrosine kinase autophosphorylation and activation. Leukemic subclones may develop mutations in the BCR/ABL kinase domain that impair imatinib binding and thereby confer drug resistance. These mutations occur chiefly in the ATP or phosphate-binding loop (P-loop), the T315I area which forms a hydrogen bond with imatinib, the M351T and E355G cluster, and the activation loop (H396R/P). Mutations of T315I are important as they may confer resistance not only to imatinib but to dasatanib and/or nilotinib. |
| Diagnosis Under Consideration |
Gleevec Resistance |
| Method |
PCR and Pyrosequencing |
| |
| Ordering Details |
| Test Code |
6290-1 |
| Turnaround Time |
24-48hrs |
| Preferred Specimen and Volume |
EDTA only (Lavender top tube). 2ML Marrow, 5ML blood |
| |
| Specimen Handling Information |
| Specimen Storage |
Refrigerated |
| Specimen Transport |
Room Temperature |
| Causes For Specimen Rejection |
No patient ID on Specimen, Patient ID on specimen and Requisition doesn't match, incorrect fixative (tube/solution), Specimen without GenPath/BioReference requisition. Frozen specimen. |
| Special Instructions |
|
| |
| Billing Information |
| CPT Codes |
83891 (1), 83900(1), 83901 (4), 83902 (1), 83904(7), 83912 (1) |
| |
| Other Information |
| Notes |
|
